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of Neurology & Neurosurgery, McGill University, Montreal, QC, Canada
de neuroimagerie fonctionnelle, Institut Universitaire de Gériatrie de Montréal, QC, Canada H3W 1W5
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Cognitive abnormalities are a feature of Parkinson’s disease (PD). Unlike motor symptoms that are clearly improved by
dopaminergic therapy, the eﬀect of dopamine replacement on cognition seems paradoxical. Some cognitive functions are improved
whereas others are unaltered or even hindered. Our aim was to understand the eﬀect of dopamine replacement therapy on
various aspects of cognition. Whereas dorsal striatum receives dopamine input from the substantia nigra (SN), ventral striatum is
innervated by dopamine-producing cells in the ventral tegmental area (VTA). In PD, degeneration of SN is substantially greater
than cell loss in VTA and hence dopamine-deficiency is significantly greater in dorsal compared to ventral striatum. We suggest that
dopamine supplementation improves functions mediated by dorsal striatum and impairs, or heightens to a pathological degree,
operations ascribed to ventral striatum. We consider the extant literature in light of this principle. We also survey the eﬀect of
dopamine replacement on functional neuroimaging in PD relating the findings to this framework. This paper highlights the fact
that currently, titration of therapy in PD is geared to optimizing dorsal striatum-mediated motor symptoms, at the expense of
ventral striatum operations. Increased awareness of contrasting eﬀects of dopamine replacement on dorsal versus ventral striatum
functions will lead clinicians to survey a broader range of symptoms in determining optimal therapy, taking into account both
those aspects of cognition that will be helped versus those that will be hindered by dopaminergic treatment.

1. Introduction
Parkinson’s disease (PD) is a neurodegenerative illness with
prominent motor symptoms of tremor, bradykinesia, and
rigidity. These motor symptoms result from degeneration
of the dopamine-producing cells of the substantia nigra,
leading to dopamine deficiency and dysfunction in the dorsal
striatum. Cognitive dysfunction has long been recognized as
a feature of Parkinson’s disease with 20–50% meeting criteria
for dementia [1–5] and a far greater proportion displaying
features of milder cognitive dysfunction [6]. Unlike the
relatively clear-cut explanation for motor symptoms, debate
has surrounded the locus of these cognitive impairments in
PD. While initial explanations focused on cortical degeneration, which also occurs in PD, particularly at later

disease stages, studies have repeatedly failed to demonstrate
correlation between cortical Lewy body dispersion and
severity of cognitive impairment [7–11]. Studies in patients
with basal ganglia lesions and investigations of cognition
in healthy volunteers using neuroimaging are increasingly
attributing cognitive functions to basal ganglia [12–17].
Some pathological studies confirm cognitive impairment in
PD patients even in the absence of cortical compromise [18,
19]. Taken together, basal ganglia pathology and biochemical
deficit might be an important cause for cognitive impairment
in PD. Further complicating our understanding of cognitive
function in PD, whereas the motor manifestations are clearly
improved by dopamine replacement medications such as L3,4-dihydroxyphenylalanine (L-dopa) or dopamine receptor
agonists, the eﬀect of dopamine replacement therapy on
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cognition seems paradoxical. Some cognitive functions are
improved by dopaminergic therapy whereas others are
unaltered or even hindered. Our main aim, in fact, is to
review and understand the eﬀect of dopamine replacement
therapy on diﬀerent aspects of cognition, relating these
findings to functions of diﬀerent segments of basal ganglia.
Previous investigations suggest that individual segments
of the basal ganglia mediate diﬀerent elements of cognition. One approach for subdividing the striatum involves
distinguishing the ventral striatum, comprising the nucleus
accumbens and the most ventral portions of caudate and
putamen, from the dorsal striatum, entailing the bulk of
the caudate nuclei and putamen [20–22]. This distinction
is important in PD given that the dopamine input to these
regions are divergent and degenerate at diﬀerent times and
to varying degrees in disease evolution. Whereas dorsal
striatum, responsible for the prominent motor symptoms,
receives dopamine input from the substantia nigra (SN),
ventral striatum is innervated by dopamine-producing cells
in the ventral tegmental area (VTA). In PD, the VTA is significantly less aﬀected than the SN at clinical disease onset and
a disparity is maintained throughout the disease course [23–
26]. Given these diﬀerences, functions performed by dorsal
striatum should improve disproportionately with dopamine
replacement therapy compared to those subserved by ventral
striatum. In fact, there is evidence that ventral striatum
functions worsen with provision of dopaminergic therapy
[13, 27–32]. An explanation oﬀered for this medicationinduced impairment is that these less dopamine-depleted
brain regions are eﬀectively overdosed by dopaminergic
medications that are titrated to dorsal striatum-mediated
motor symptoms [13, 28, 29, 32].
A central objective of this paper is therefore to define
the diﬀerent cognitive processes mediated by the more
dopamine-depleted dorsal compared to the relatively spared
ventral striatum, with the aim of providing a framework
for predicting and understanding those cognitive processes
that might be enhanced compared to those that will be
hindered by dopaminergic therapy, at least at the early stages
of the disease. Albeit somewhat simplified in that it does not
address the impact of, nor incorporate findings related to,
other VTA-innervated regions, such as prefrontal and limbic
cortex, we will show that this approach accommodates and
explains an impressive array of cognitive and neuroimaging
findings in PD, providing a possible principle to predict and
understand the eﬀect of dopamine replacement therapy on
cognition in this disease.
We will first present subtle cytoarchitectonic distinctions
between dorsal versus ventral striatum, as well as the
divergent regions to which they are reciprocally connected,
as evidence of how these regions are diﬀerentially adapted to
separate cognitive functions. We will next review the eﬀect
of dorsal versus ventral striatum lesions on cognition, as
well as the cognitive functions that implicate dorsal versus
ventral striatum in neuroimaging studies. As a test of the
framework adopted here, that dorsal striatum functions are
improved whereas ventral striatum functions are worsened
by dopamine replacement, we will next compare those
cognitive functions that are known to be improved versus
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those that are impaired by dopamine replacement therapy
in PD patients to the pattern predicted by the lesion and
neuroimaging studies. Table 1 summarizes these findings.
Finally, we will survey the results of neuroimaging studies in
PD patients on and oﬀ dopamine replacement therapy. These
studies provide direct evidence of the eﬀect of dopamine
supplementation on brain activity in PD. Further, they
provide an additional test of the hypothesis that variable
eﬀects of dopamine treatment in PD on distinct cognitive
processes relate to their diﬀerential reliance on dorsal and
ventral striatum.
1.1. Dorsal Striatum. In the dorsal striatum there are
denser dopamine inputs and more numerous dendrites
and spines on medium spiny neurons (MSNs) resulting
in rapid and maximal dopamine stimulation through a
wide range of input firing frequency and intensity [22, 33].
Due to high concentration of dopamine transporter (DAT),
which is responsible for synaptic dopamine reuptake and
clearance, synaptic dopamine is rapidly cleared, yielding
short dopamine stimulation durations [22]. Taken together,
this precisely-timed, brief, and consistently maximal receptor
stimulation adapts dorsal striatum for rapid, flexible, and
more absolute or binary responding as might be needed
in deciding between alternatives. Suggesting an important
role in performance, the dorsal striatum is reciprocally
connected to a number of eﬀector brain regions such
as frontal eye fields, dorsal and rostral premotor cortex,
supplementary, and primary motor cortex. Dorsal striatum projections also arise from and lead to dorsolateral
prefrontal, somatosensory, and parietal association cortices,
regions involved in executive functions [34]. In addition to
an extremely high degree of convergence in striatum, MSNs
receive very few projections from each cortical neuron [35–
38]. Dorsal striatum is consequently ideally positioned to
sum diverse influences on responding, with vast numbers
of cortical neurons each making only small contributions,
requiring a concordance among many inputs to influence the
excitation status of a given MSN. In turn, through reciprocal
connections, single MSNs aﬀect numerous cortical neurons.
In this way, dorsal striatum coordinates activity in disparate
cortical regions. These characteristics would suggest that
dorsal striatum is ideally suited for selecting some stimuli or
responses and suppressing others.
1.2. Ventral Striatum. Subtle cytoarchitectonic and neurochemical diﬀerences for ventral relative to dorsal striatum,
such as smaller neuron size with fewer and more widelyspaced dendrites and spines, along with less significant
dopaminergic input, have as a functional consequence that
receptor stimulation with a single dopamine pulse is slower,
and of lower and more variable intensity than in dorsal striatum [22]. This translates to greater diﬀerences comparing
tonic versus phasic dopamine stimulation in ventral striatum, a fact demonstrated experimentally by Zhang et al. [33]
who found nearly maximal dorsal striatum stimulation at
even the lowest intensity and frequency dopamine impulses
compared to much more graded, incremental responses in
the ventral striatum. Owing to lower DAT concentration,
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Table 1: Cognitive functions that are enhanced, unchanged, or impaired by dopaminergic therapy, grouped according to their association
with dorsal striatum, ventral striatum, or other brain regions.
Enhanced by dopaminergic therapy
∗

Ventral striatum

Dorsal striatum

Other brain
regions

∗

Unchanged by dopaminergic
therapy

Motivation
Impulsivity

Selective attention
Selective responding
Complex planning
Category judgements
Time estimation
Visuospatial processing
Explicit and implicit retrieval
Set shifting
Task switching
Spatial working memory
Manipulating contents of working
memory

Complex planning
Set shifting
Task switching

Nonspatial working memory
Set shifting
Task switching

∗

Impaired by dopaminergic therapy
Implicit and explicit learning
Reversal learning
Orienting to stimuli
Time estimation

Simple reaction time
Production of self-generated
sequences
Generation of alternate uses of
common objects

Are enhanced to a pathological degree.

dopamine stimulation is also of longer duration in ventral
compared to dorsal striatum [22]. Together, these characteristics make the ventral striatum well suited for associating
stimuli or events, even across time, in a graded fashion as
would be essential for probabilistic or associative learning
and for binding events that are temporally coincident into
episodes. The regions to which ventral striatum are reciprocally connected also suggest its involvement in encoding
and associating salient features of the environment. The
ventral striatum receives inputs from and projects to anterior
cingulate, orbitofrontal, and anterior temporal cortices, as
well as to hippocampus, insula, amygdala, and hypothalamus. Due to a high degree of convergence, with 10–20 000
cortical or limbic neurons projecting to a single medium
spiny neuron in the striatum, representations in basal ganglia
are highly sparse relative to corresponding representations in
cortex and limbic regions [35–38]. This degree of abstraction
precludes storing of memory engrams within ventral striatum but given its significant reciprocal interconnectedness
to multiple regions simultaneously, ventral striatum receives
information about (a) top-down, goal-directed attentional
biases, (b) bottom-up object and event salience, (c) multimodal representations of objects and events, and (d) the
current motivational state of the organism [20]. Given persistence of stimulation, ventral striatum can further incorporate response outcome and reward information. Because
connections to these diverse cortical and limbic regions are
reciprocal, ventral striatum is in a position to harmonize
activity in these distant brain regions as is needed for associating disparate, temporally coincident features into episodes.
These anatomical characteristics suggest that ventral striatum could play an important role in learning and encoding.

2. Cognitive Testing (a) in Patients
with Basal Ganglia Lesions and (b) Using
Neuroimaging in Healthy Volunteers
2.1. Dorsal Striatum. Lesions in the dorsal striatum have
been shown to impair set shifting and task switching
(e.g., [39–42] but see [43–46]), category judgements [41],
and suppression of irrelevant information and responses,
particularly when the ignored stimulus is highly salient and
the to-be-avoided response is over-learned (e.g., [39, 40, 44,
45] but see [46, 47]). Patients with dorsal striatum lesions
have been shown in one study to have deficits in reversal of
previously acquired stimulus-reward relations [48]. Tests of
planning (e.g., tower of Hanoi and porteus mazes [49]) and
visuospatial processing [50–52] uncover deficits in patients
with dorsal striatum lesions. A number of lesion studies have
also revealed deficits in explicit (e.g., [39, 44, 49, 52, 53]
but see [46]) and implicit memory [53, 54] but see [55].
Working memory [39, 41, 44, 48], language (e.g., [39, 56]
but see [43, 57]), word and face recognition (e.g., [39, 43]
but see [58]), as well as explicit [53] and implicit learning
(e.g., [41, 51, 53, 59–61] but see [49, 62]), in contrast, tend
to be spared.
Consistent with these lesions studies, shifting set and
changing stimulus-reward or stimulus-response mappings
(e.g., [63–66] but see [15]) are associated with increased
activity in dorsal striatum. Responding to less well learned
dimensions such as colour versus word in the Stroop task
[12] or with less-practiced responses, as when pictures are
named in a second language relative to a first language [67],
also preferentially activate dorsal striatum. In a similar vein,
dorsal striatum is more engaged when responding to a target
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location that was inaccurately predicted by a cue when cues
had previously been predictive of the correct target location
[68]. That is, dorsal striatum is engaged when previously
informative stimuli must now be disregarded.
Dorsal striatum is preferentially activated for learned
relative to random motor sequences [69], for familiar
items in an episodic recognition test [70], during category
judgements [17, 71], especially when there is significant
category uncertainty [72], for rewarded relative to unrewarded stimuli [17, 73] and responses [74, 75], and in
distinguishing and estimating diﬀerent time durations [76–
85]. Dorsal striatum activity remains significantly increased
above baseline throughout these experiments, well after
sequences, categorization rules, or stimulus-reward and
response-reward relations have been acquired, suggesting
that dorsal striatum is involved in performance rather than
learning. Tests of visuospatial processing, such as mental
rotation, further implicate dorsal striatum in fMRI, although
significant increases in activity were noted for male subjects
only [86].
Dorsal striatum has been associated with risk aversion
during decision making [87] although preferential activation
has been noted when speed is emphasized over accuracy in
a motion judgement task [88]. Recent findings implicated
dorsal striatum in encoding the joint dimensions of reward
magnitude and subjective value (i.e., marginal utility) as well
as temporal discounting, supporting a role for the dorsal
striatum in integrating divergent influences on decision
making [89, 90].
2.2. Ventral Striatum. There have been very few examinations of cognition following lesions circumscribed to
the ventral striatum, mostly owing to the rarity of such
small and strategically placed lesions. In human participants,
Goldenberg and colleagues [91] reported a case of anterograde amnesia for verbal material following a left nucleus
accumbens bleed. Despite an inability to learn new verbal
material whether testing memory with recall or recognition,
this patient performed normally on tests of retrospective
verbal memory, divided and shifting attention, Wisconsin
card sorting (WCST), tower of London (TOL), working
memory, language, encoding and retrieval of nonverbal
information. Taken together, this pattern of deficits and
spared functions suggests a critical role for the ventral
striatum in encoding associations, with left ventral striatum
lateralized for language. Calder and colleagues [92] revealed
anger recognition deficits in 3 patients with left and 1 patient
with right ventral striatum lesions despite otherwise normal
visual processing. Martinaud and colleagues [93] found that
left ventral striatum lesions, following anterior communicating artery aneurysm, were associated with behavioural
deficits, reduced daily activities, and hyperactivity. Finally,
Bellebaum and colleagues [48] looked at acquisition and
reversal of stimulus-reward associations in 3 patients with
isolated ventral basal ganglia lesions compared to patients
with dorsal or dorsal plus ventral basal ganglia lesions as well
as to control participants. All patients, irrespective of group,
displayed deficits in reversing previously acquired stimulusreward contingencies. There were no specific or consistent
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patterns noted for patients with ventral basal ganglia lesions
in their experiment, consequently.
Functional magnetic resonance imaging (fMRI) experiments have shown that the degree to which a motor sequence
is implicitly learned correlates with ventral striatum activity
[69] and that ventral striatum activity is greatest early in
learning, and is preferential for positive feedback relative to
negative feedback during initial learning [17, 74, 94, 95]. This
ventral striatum-mediated, stimulus-reward learning occurs
even without intention or consciousness [96]. Ventral striatum activity drops oﬀ as performance asymptotes [69]. Once
learning is established, ventral striatum activity increases
over baseline tasks only (a) for unexpected rewards delivered
for previously unrewarded stimuli or when reward is omitted
for previously rewarded items (i.e., prediction errors; [97–
102]), (b) for punishment after errors [103], or (c) in reversal
learning experiments when criterion is reversed and selection
of previously rewarded stimuli now elicits negative feedback
[17, 65, 104–106]. Ventral striatum is diﬀerentially activated
by salient [107–109], valued [107, 108, 110, 111], or novel
stimuli [17, 112], and even for passively received monetary
or social rewards [113]. Diﬀerential ventral striatum activity
reflects both magnitude and probability of reward [114], as
well as probability of a given outcome (e.g., [115–117] but
see [114]). Taken together, the ventral striatum seems to be
engaged when a stimulus or event in the environment signals
the possibility of new learning.
Heightened ventral striatum activity has been shown in
a number of studies to be associated with more impulsive
choices [118, 119] and ventral striatum has not been implicated in response inhibition or response stopping [120, 121].
Ventral striatum activity is greater for riskier choices [118,
119, 122, 123] and for more immediate rewards (i.e., temporal discounting; [124–126]). Further, negative functional
interaction between nucleus accumbens and anteroventral
prefrontal cortex was associated with decisions favouring
long-term goals relative to an immediate reward [127]. That
is, high levels of activity in nucleus accumbens correspond to
lower anteroventral prefrontal cortex activity, which in turn
was associated with decisions favouring immediate rewards
over long-term objectives.
Consistent with findings in patients with ventral striatum
lesions, neuroimaging studies have found that nucleus
accumbens activity associates with encoding of facial emotional expressions [128]. Mühlberger and colleagues [129]
further showed that ventral striatum activity was greater
when control participants observed changes from angry to
happy or neutral facial expressions. Finally, Liang and colleagues [130] found that ventral striatum activity correlated
with extremes of facial attractiveness.
2.3. Summary: Cognitive Testing (a) in Patients with Basal
Ganglia Lesions and (b) Using Neuroimaging in Healthy Volunteers. The dorsal striatum is implicated in selecting among
various stimuli and competing responses, when divergent
influences impinge on decision making and particularly
when selection requires discounting more salient stimuli or
overriding prepotent responses. Dorsal striatum is involved
in complex planning tasks and in distinguishing among
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groups of stimuli and responses, tracking whether an item
belongs to one category over another, is rewarded versus
unrewarded, or is familiar versus novel. The dorsal striatum
is implicated in time discrimination and estimation, as well
as in visuospatial processing. From this review, we surmise
that, whereas individual cortical regions might be specifically
sensitive to separate aspects of a stimulus, situation, or event,
such as salience, preference, motivational value, reward,
speed, or accuracy, the dorsal striatum integrates all of
these influences to yield an optimal, considered criterion,
that maximizes and regulates accurate decision making,
selective responding, and planning. Conversely, the dorsal
striatum’s necessity is significantly lessened for decisions
that can be accomplished relying on a single dimension
to guide behaviour—particularly if this dimension is most
salient [15]. This could account for the inconsistent findings
with respect to task- or set shifting deficits in patients with
dorsal striatum lesions and for the occasional finding that
these tasks do not preferentially activate dorsal striatum in
neuroimaging investigations. An aim of future studies should
be to better understand these inconsistencies.
In contrast, both lesion and neuroimaging studies suggest that the ventral striatum is extensively implicated in
multiple aspects and forms of learning. Ventral striatum
is involved in orienting attention to salient, novel, or
valued stimuli and seems to mediate motivation, facilitating
approach behaviours. Finally, some evidence suggests that
ventral striatum might have a role in facial emotional
processing. Both implicit and explicit learning and tests of
implicit and explicit memory implicate ventral striatum.
Unlike hippocampus and associated temporal cortex that
seem specialized for encoding information when memory is
subsequently explicitly probed, ventral striatum is implicated
in more generalized encoding function. To our knowledge,
no studies have examined this issue as a central aim and we
are currently investigating this question.

3. Effect of Dopamine Replacement
Therapy on Cognition
A number of studies have investigated the eﬀects of
dopamine replacement therapy on cognition in PD. At
first blush, these results seem paradoxical. Whereas inconsistencies in this literature surely owe, at least in part,
to diﬀerences in sample size, diverse methodologies, discrepancies in patient characteristics, such as age, disease
duration and severity, PD-dominant side, and even genetic
profile, we postulate that the diﬀerential reliance on the
dorsal and ventral striatum of the cognitive function under
investigation, accounts for most of this variability.
The dorsal striatum is significantly depleted of dopamine
at all stages of clinical PD. The ventral striatum, in contrast,
is substantially less dopamine deprived, especially early in
the disease course. Because dopaminergic supplementation
is titrated to dorsal striatum-mediated striatum motor
functions, it is suggested that ventral striatum is overdosed
and its functions are impaired whereas dorsal striatum
becomes dopamine replete and operations that it mediates
are improved. We test this explanation for the eﬀect of
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dopaminergic therapy on cognitive functions in PD, by
relating (a) the pattern of cognitive improvements and
impairments subsequent to dopamine replacement in PD, to
(b) the cognitive functions that seem attributed to the dorsal
and ventral striatum outlined above.
3.1. Cognitive Functions Improved by Dopamine Replacement
Therapy in PD. A number of studies have shown that
administration of dopamine replacement therapy improves
cognitive function in patients with PD. Impairments for PD
patients in switching attention from one stimulus dimension
[131–135] but see [29], or one response to another [134,
136], as well as in selecting between alternatives with
high response conflict [137] are redressed by dopamine
replacement. Similarly, although maintenance and retrieval
of nonspatial information in working memory per se seems
to be unaﬀected by dopaminergic therapy ([138–140] but
see [141, 142]), medication improves manipulation of the
contents of working memory [138, 139]. Patients were
impaired on a measure of verbal fluency compared with
normal controls when tested oﬀ medication but there were
no group diﬀerences on medication [29]. Remembering to
perform an action at a specified time, so-called prospective
remembering, was impaired in PD patients tested oﬀ but
not on medication [143, 144]. Impairment in generating
lines of varying lengths—an action planning deficit—in
PD patients was improved with dopamine replacement
whereas a deficit in repeatedly producing lines of only two
lengths in the simple figure replication condition was not
[145]. Also suggesting motor planning improvement with
dopaminergic medication, PD patients on dopamine medication demonstrated better and normalized chunking of
motor movements [146], despite normal sequence learning
both oﬀ and on medication. In a similar vein, although
learning simple stimulus-response relations was unaltered by
dopamine replacement, chaining these learned associations
to achieve a long-term goal was impaired in PD patients
tested oﬀ medication. Chaining these events to achieve
the end goal was improved when patients were tested on
dopaminergic therapy [147]. Whether these results owe to
a medication-remediable deficit in planning, learning, or
retrieval, is unclear, however. Together, the findings surveyed
above dopamine repletion improves cognitive flexibility,
planning, and possibly long-term retrieval.
In contrast to nonspatial working memory, spatial
working memory deficits have been shown to improve
with dopaminergic treatments [148–151], perhaps related
to improvement in visuospatial processing. Consistent with
the latter interpretation, category-specific (i.e., animals)
object recognition using degraded images has been shown
to be compromised in de-novo PD patients relative to
PD patients receiving dopaminergic therapy and healthy
controls. This deficit was remediated with introduction of
dopamine replacement medications [152].
Finally, a number of studies have demonstrated impaired
behavioural performance on time estimation and motor
timing tasks in PD patients relative to controls. These deficits
improve with dopaminergic medication ([153–156] but see
[157, 158]).
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3.2. Cognitive Functions Unaﬀected by Dopamine Replacement Therapy in PD. Some studies have revealed no eﬀect
of dopamine replacement therapy on cognitive function.
Shifting to a previously irrelevant dimension was impaired
in PD patients relative to controls but was not improved by
administration of L-dopa [27, 138, 139]. PD patients were
impaired compared to controls in generating proper names
but this impairment was not improved with dopamine
replacement [159]. Nagano-Saito and colleagues [160] found
no improvement on performance of the TOL on dopamine
agonist relative to oﬀ medication.
3.3. Cognitive Functions Impaired by Dopamine Replacement
Therapy in PD. Learning was most commonly impaired in
PD patients tested on dopamine replacement therapy. A
number of studies have revealed deficits after dopamine
replacement in probabilistic associative learning, although
PD patients oﬀ medication performed equivalently to
controls [29, 140, 158]. Shohamy and colleagues [161]
found that dopaminergic medication impaired learning of
an incrementally acquired, concurrent discrimination task,
whereas oﬀ medication PD patients performed as well as
controls. Sequence learning was reduced for PD patients
on medication [146, 162–164]. Dopamine supplementation
in PD patients yielded reduced facilitation for consecutive,
consistent stimulus-stimulus pairings in a selection task
compared to normal implicit learning and hence facilitated responding when tested oﬀ medication [137]. Once
stimulus-reward associations have been learned, reversing
probabilities of stimulus-reward associations is also impaired
for PD patients on dopamine replacement therapy [27,
32, 40, 104, 165–167]. Finally, dopamine therapy impaired
learning from negative feedback [168].
Another frequent deficit in PD patients on dopamine
replacement therapy is in impulse control [27, 169]. As
an example, impulsive betting despite appropriate and
deliberate decision making was noted following L-dopa
administration in PD patients [132, 140]. L-dopa therapy
in PD patients has been shown to increase the tendency to
choose earlier relative to later rewards, regardless of reward
magnitude (i.e., temporal discounting) compared to decision
making on placebo. Dopaminergic therapy, particularly
dopamine agonist use, in PD has clearly been shown to
increase a number of impulse control disorders such as
pathological gambling, compulsive sexual behaviour, compulsive buying, and binge eating [170, 171]. The dopamine
dysregulation syndrome in which PD patients overuse their
dopamine replacement medications is a further example
of enhanced motivation toward rewarding behaviours with
therapy [172].
Simple reaction time was increased with administration
of L-dopa [173] and apomorphine [174]. Time estimation
in the seconds but not millisecond range was impaired in
patients on relative to oﬀ medication and healthy controls
[155, 175]. Finally, impairment in generation tasks such
as subject-ordered pointing [29] or production of alternate
uses for common objects [167] have also been noted in PD
patients on medication.
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3.4. Eﬀect of Dopamine Therapy in Healthy Controls. A number of studies have investigated the eﬀect of dopaminergic
modulation on cognitive function in healthy volunteers.
Breitenstein and colleagues [176] found that administering a
dopamine agonist significantly impaired novel word learning
in healthy volunteers compared to placebo. Similarly, Pizzagalli and colleagues [177] and Santesso and colleagues [178]
found that reward learning was impaired in healthy human
volunteers after administering a single dose of pramipexole.
Probabilistic reward learning relies on the ventral striatum
[74, 94, 96] and consequently these findings strengthen
the contention that impaired learning in PD patients on
medication results from overdose of VTA-innervated ventral
striatum. Pine and colleagues [90] showed that in healthy
controls administration of L-dopa increased temporal discounting in a decision making task, with more numerous
smaller but sooner reward choices relative to larger but later
reward options, compared to performance after receiving
placebo or haloperidol. Schnider and colleagues [179] found
that L-dopa, but not risperidone or placebo, increased
false positive responses, without altering overall memory
performance, in healthy volunteers tested in a memory
paradigm that had previously been shown to be sensitive
in confabulating patients. These findings suggest a less
conservative response criterion compatible with increased
impulsivity seen with dopamine replacement in healthy
volunteers, paralleling findings in PD. Finally, Luciana and
colleagues [180] found that bromocriptine, a dopamine agonist, facilitated spatial delayed but not immediate memory
performance in healthy volunteers.
Conversely, others have investigated the eﬀect of
dopamine receptor antagonists on cognition in healthy volunteers with the aim of simulating the dopamine deficiency
in PD. Set shifting impairments have been induced by this
manipulation, consistent with performance of PD patients
oﬀ medication [30]. Similarly, Nagano-Saito and colleagues
[181] showed that after consuming a drink deficient in the
dopamine precursors tyrosine and phenylalanine, post-set
shift response times were increased in the WCST compared
to when they performed the task, after consuming a drink
balanced in amino acids. Finally, the eﬀect of dopamine
receptor antagonism on working memory in healthy controls
has been inconsistent [30, 182, 183].
3.5. Summary: Eﬀect of Dopamine Replacement Therapy on
Cognition. Based on our review, the pattern of improvements and impairments in PD patients following dopamine
supplementation are well accounted for by diﬀerential baseline dopamine innervation of the dorsal and ventrals striatum, with very few exceptions. Consistent with conclusions
about cognitive functions ascribed to dorsal striatum arising
from lesion and neuroimaging studies, selecting among alternative stimuli and responses, particularly when there is high
conflict or when enacting a decision requires disregarding
previously relevant stimulus dimensions or responses, is
improved by dopamine replacement in PD. Also consistent with lesion and neuroimaging studies, dopaminergic
therapy remediates long-term memory retrieval, planning,
visuo spatial processing, as well as time estimation and
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motor-timing deficits. Providing convergent evidence for
dopamine’s modulatory role in these executive functions,
dopamine antagonists in healthy volunteers have been shown
to impair set shifting.
Numerous studies reveal impaired learning in PD
patients on relative to oﬀ dopamine replacement therapy
as would be expected in reviewing lesion and neuroimaging studies of ventral striatum function. Impaired simple
reaction time in PD patients on medication, which could
owe to impaired orienting, also would not be inconsistent
with functions ascribed to ventral striatum from our survey
of lesion and neuroimaging studies. Further bolstering the
dopamine overdose hypothesis to account for deterioration
of some cognitive functions in medicated PD patients,
dopaminergic therapy in healthy volunteers actually impairs
learning, exactly paralleling the pattern observed in PD
patients. To reiterate, the central contention of the dopamine
overdose hypothesis is that because the VTA is relatively
spared and hence ventral striatum dopamine is adequate,
especially early in PD, dopamine replacement, dosed to
remediate the dorsal striatum-mediated motor symptoms,
eﬀectively causes an over-supply of dopamine to the ventral
striatum, interfering with its function.
Not consistent with the view that dopamine overdose disrupts ventral striatum-mediated processes, increased impulsivity in PD patients on dopamine replacement actually
suggests an enhancement of ventral striatum function. Lesion
and imaging studies have shown that ventral striatum mediates motivation, approach behaviour, and impulsive choices.
Also paralleling findings in PD, dopamine replacement in
healthy volunteers increases impulsive choices and enhances
false positive responses in a memory paradigm, consistent
with greater impulsivity. While still in line with an account of
ventral striatum dopamine over-supply, these findings cannot be explained by the claim that dopamine excess interferes
with functions of ventral striatum. We submit that a possible
explanation for opposing eﬀects of dopamine replacement
on these ventral striatum-mediated functions could owe to
their diﬀerential reliance on phasic or relative, versus tonic
or absolute dopamine receptor stimulation. In reviewing
biological features of the ventral striatum, low tonic, with
graded phasic dopamine responses, sensitive to frequency
and degree of stimulation, are characteristics that render the
ventral striatum particularly suited for encoding associations
between stimuli, responses, outcomes, or events. If these
graded dopamine signals convey strength of association then
administration of bolus dopamine therapy could conceivably
interfere with this encoding. Further, decreased DAT for
clearing synaptic dopamine makes the ventral striatum even
more vulnerable to disruption by bolus dopamine administration. In contrast, those functions of ventral striatum
that depend on absolute dopaminergic tone and not upon
extracting information from degree of dopamine receptor
stimulation or from relative signal-to-noise ratio might be
increased, albeit to a pathological level, by dopaminergic
therapy. Impulsivity, an inclination to act prematurely
without adequate consideration of relevant determinants of
behaviour, might depend on absolute dopaminergic tone
in the ventral striatum. Administration of dopaminergic
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therapy and consequent ventral striatum dopamine overdose
might enhance this tendency to a detrimental degree.
Some studies have revealed no eﬀect of dopamine
replacement therapy on cognitive function. Possibly reflecting bias against publishing null results, there are far fewer
examples of functions that are neither helped nor hindered
by dopaminergic therapy in PD and hence a clear trend
does not emerge. Given a variety of reasons for statistical
equivalence, such as true equality between conditions and
populations, inadequate power to detect diﬀerences, as well
as a 20% Type 2 error rate compared to a more acceptable
5% Type 1 error rate, interpretation of null results can be
problematic and should be done cautiously.
Remediable deficits in verbal fluency and in manipulating the contents of working memory with administration
of dopaminergic therapy are not clearly predicted by the
dorsal striatum lesion and neuroimaging studies. Further,
time estimation has been attributed to dorsal striatum
[14, 15, 39–42] and therefore impairment in this process
with dopamine replacement would not be explained by the
simple framework applied here. Finally, decreased response
generation with medication is not predicted by the lesion
and neuroimaging literature reviewed here. These few inconsistencies might relate to eﬀects of dopamine replacement
on other brain regions, particularly those that also receive
input from the relatively-spared VTA, such as prefrontal
and limbic cortices, that we have not discussed in this
review. Alternatively, a more complete understanding of
the functions of the dorsal and ventral striatum might
resolve these discrepancies. Overall, however, the framework
adopted in this review accommodates a significant number
of findings, despite the few inconsistencies encountered.
Next, we review neuroimaging studies in PD patients on and
oﬀ medication.

4. Functional Neuroimaging in PD
4.1. Neuroimaging in PD Patients oﬀ Dopaminergic Medication. Neuroimaging studies of patients with PD have
revealed diﬀerences in regions of activation and de-activation
at rest. A number of investigations have shown increased
activity in the thalamus, globus pallidus, pons, and primary
motor cortex compared to reductions in lateral premotor and
posterior parietal areas [184]. Those patients who were not
demented but performed abnormally on neuropsychological
tests relative to controls additionally revealed reductions in
medial prefrontal regions, dorsolateral prefrontal cortex, premotor cortex, rostral supplementary motor area, precuneus,
and posterior parietal regions along with relative increases in
cerebellar cortex and dentate nuclei [184].
Changes in patterns of activation are also described in PD
patients oﬀ medication performing cognitive tasks. Investigating the eﬀect of retrieval and manipulation of working
memory contents on default mode network in PD patients
oﬀ medication, van Eimeren and colleagues [185] found that
PD patients only appropriately deactivated medial prefrontal
cortex and in fact increased activation of precuneus and
posterior cingulate cortex. The default network involves
precuneus, medial prefrontal, posterior cingulate, lateral
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parietal, and medial temporal cortices and is characterized
by deactivation during the performance of executive tasks
in healthy volunteers [186, 187]. Connectivity analysis also
revealed that medial prefrontal cortex and the rostral ventromedial caudate nucleus were functionally disconnected in
PD, further supporting disturbance of the default network in
PD. Others have found that hypometabolism and decreased
endogeneous dopamine in dorsal striatum, as measured by
[18 F]DOPA PET, [11 C]-raclopride (RAC) PET, or fMRI, are
directly correlated with poorer performance on the WCST
and on tests of working, verbal, and visual memory in PD
patients [188–190]. Schonberg and colleagues [191] further
showed decreased prediction error signals in dorsal striatum
in a reinforcement learning study using fMRI in PD relative
to controls. Finally, dorsal-striatum-involving tasks (e.g.,
set-shifting under uncertainty in card sorting tasks) also
reveal decreased activations in striatum-associated cortical
regions such as posterior parietal regions, ventrolateral and
dorsolateral prefrontal cortex when planning a set shift,
as well as in premotor cortex during set-shift execution
[14, 192].
In contrast, activity in the ventral striatum and cortical
regions to which it is reciprocally connected, is comparable
or, rarely, is enhanced in PD patients oﬀ medication
compared to controls in neuroimaging studies. As previously noted, medial prefrontal cortical regions—reciprocally
connected to ventral striatum and innervated by VTA—
appropriately deactivate during an executive task in PD
patients oﬀ medication [185]. Prediction error signals in a
reinforcement learning study using fMRI, were normal in
the ventral striatum in PD patients tested oﬀ medication,
despite impairments in the dorsal striatum. Sawamoto and
colleagues [190] found that the same contrast of spatial
working memory versus visuomotor processing that yielded
hypometabolism in dorsal caudate for PD patients relative
to controls, showed comparable between-group activity in
anterior cingulate, a region reciprocally connected to the
ventral striatum and receiving dopamine input from VTA.
Finally, PD patients revealed increased activations relative
to controls in prefrontal and posterior parietal cortex for
cognitive processes that did not implicate caudate nucleus,
such as in conditions that required neither planning nor
executing a set shift in a card sorting task [14, 192].
This enhanced cortical activity was associated with poorer
cognitive performance, however.
4.2. Summary: Neuroimaging Results in PD Patients oﬀ
Dopaminergic Medication. Overall, these imaging studies
are consistent with the notion that decreased cognitive
performance in PD relates primarily to dopaminergic deficit
and dysfunction of the dorsal striatum. Functional impairments owe to dorsal striatum dysfunction per se as well as
to consequent deregulation of cortical networks involving
dorsal striatum. These investigations further support that in
undemented PD patients, ventral striatum and its cortical
networks are unperturbed in the oﬀ state, which we attribute
to preserved VTA dopaminergic function. On occasion,
increased cortical activity is noted for PD patients oﬀ
dopaminergic medications relative to controls, although
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this does not necessarily translate to improved cognitive
performance [14, 149, 192]. Increased number and extent
of some cortical regions recruited by PD patients while
performing cognitive tasks oﬀ medication, could owe to
aberrant up-regulation of regions that are normally opposed
or inhibited by dorsal striatum and its cortical networks.
Studies aimed specifically at contrasting dorsal versus ventral
striatum-mediated cognitive functions in PD patients oﬀ
medication relative to controls using neuroimaging are
lacking. These studies are needed not only to directly assess
the diﬀerential metabolic impairments of the dorsal and
ventral striatum in PD but also to understand the impact,
if any, of dorsal-striatum dysfunction on baseline ventral
striatum metabolic function, independent of medication.
The section that follows summarizes the eﬀects of dopamine
replacement in PD patients and dopamine modulation in
healthy controls on patterns of brain activity assessed by
functional neuroimaging.

5. Effect of Dopamine Modulation on
Brain Activity
5.1. Normalization of Neuroimaging Patterns with Dopaminergic Therapy in PD Patients. In the resting state, Wu and
colleagues [193] found that PD patients in the oﬀ state
had significantly decreased functional connectivity between
the supplementary motor area, left dorsolateral prefrontal
cortex, and left putamen, along with increased functional
connectivity among the left cerebellum, left primary motor
cortex, and left parietal cortex compared to normal subjects.
Administration of L-dopa normalized the pattern of functional connectivity in PD patients with degree of restoration
correlating with motor improvements as assessed by the
Unified Parkinson’s Disease Rating Scale (UPDRS) motor
score. Similarly, Feigin and colleagues [194] and Asanuma
and colleagues [195] revealed at rest, a decrease in activation
of the globus pallidus and subthalamic nuclei and an increase
in cortical motor and premotor activity with administration
of L-dopa, constituting a correction in the Parkinson’s
disease related motor pattern.
Investigating the eﬀect of dopamine replacement on
neuroimaging patterns in PD patients performing cognitive tasks, Cools and colleagues [196] found that Ldopa eﬀectively normalized cerebral blood flow in PD
patients compared to controls, decreasing activity in the
right dorsolateral prefrontal cortex during performance of
both planning and spatial working memory tasks compared
with a visuomotor control task, and increasing cerebral
blood flow in the right occipital lobe during a memory
task relative to a control task. Mattay and colleagues [149]
found that dopamine replacement increased activity in
motor brain regions and decreased activity in the prefrontal
cortical regions, constituting a correction of the PD pattern
and correlating with decreased error rates on a working
memory test. Fera and colleagues [197] showed that PD
patients oﬀ medication had increased Stroop interferencerelated activity in anterior cingulate and presupplementary
motor cortex compared to controls. L-dopa administration
attenuated responses in these regions and increased activity
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in prefrontal cortex, which correlated with more accurate
Stroop performance. Jahanshahi and colleagues [158] found
that in PD patients oﬀ medication, motor timing tasks
activated bilateral cerebellum, right thalamus, and left
midbrain relative to a control, reaction time task whereas
for healthy volunteers this contrast revealed significantly
increased activity in left medial prefrontal cortex, right hippocampus, bilateral angular gyrus, left posterior cingulate,
and left nucleus accumbens and caudate. Administration of
a dopamine agonist increased activity in prefrontal regions in
PD patients and was associated with improved performance.
In PD patients, administration of apomorphine during
performance of the TOL revealed greater deactivation of
ventro-medial prefrontal cortex, a region belonging to the
default network, as a function of task complexity [160].
Finally, Jubault and colleagues [198] found that treatment
with dopaminergic therapy had no eﬀect on brain activity
in regions implicated in planning a set shift (i.e., caudate
nucleus, ventrolateral, posterior, and dorsolaterlal prefrontal
cortex) in PD patients but increased activity in the premotor
cortex, essentially normalizing the pattern observed for setshift execution.
5.2. Impairment of Neuroimaging Patterns with Dopaminergic
Therapy in PD Patients. In some cases, administration
of L-dopa is associated with abnormal patterns of brain
activity in PD. Feigin and colleagues [162] found that
administration of L-dopa reduced sequence learning and was
associated with enhanced activation in the right premotor
and decreased activity in the ipsilateral occipital association
area compared to controls. Argyelan and colleagues [199]
showed that L-dopa diminished learning-related ventromedial prefrontal cortex suppression in a sequence learning
task compared to unmedicated PD patients and healthy
controls. In PD patients, administration of L-dopa correlated
with greater attenuation of the dorsal striatum, insula,
subgenual cingulate, and lateral orbitofrontal cortices for
delayed relative to more immediate rewards, paralleling the
behavioural result of increased impulsivity and temporal
discounting relative to placebo [90]. Steeves and colleagues
[200] found decreased binding of the D2 receptor ligand
RAC in the ventral striatum in PD patients with pathological
gambling relative to PD patients not known for pathological gambling, following administration of a dopamine
agonist during gambling and control tasks. Along similar
lines, using H2 [15 O] PET to measure regional cerebral
blood flow as an index of regional brain activity during
decision making with probabilistic feedback, van Eimeren
and colleagues [201] compared PD patients with and
without DA-induced pathological gambling before and after
apomorphine administration. Pathological gamblers evidenced a dopamine agonist-induced attenuation of impulse
control and response inhibition brain regions such as
lateral orbitofrontal cortex, rostral cingulate, amygdala, and
external pallidum whereas nongamblers revealed increased
activity in these brain regions with administration of a
dopaminergic agonist. These results suggest good correlation
between the general behavioural eﬀects and changes in
neural activity precipitated by dopamine replacement, but
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highlight that individual diﬀerences can also augment or
mitigate these correlations. Finally, Delaveau and colleagues
[202] investigated the eﬀect of L-dopa on brain regions
associated with facial emotion recognition. They found that
L-dopa decreased task-associated amygdala activation in PD
patients.
5.3. Eﬀect of Dopamine Modulation in Healthy Controls. In
healthy elderly volunteers, administration of apomorphine, a
dopamine agonist, resulted in improved performance on the
TOL task [160]. Performance on TOL produced deactivation
in ventro-medial prefrontal cortex and posterior cingulate
cortex, regions belonging to the default mode network,
both on and oﬀ medication. On apomorphine, there was
an inverse correlation between task complexity and ventromedial prefrontal cortex [160]. In this example, a dopamine
agonist improved performance and enhanced connectivity of
underlying brain networks. Given that these patients were
elderly, the authors speculated that as aging is related to
dopamine cell loss, apomorphine could have corrected a
clinically nonmanifest dopaminergic deficit in their controls.
In most cases, however, dopamine modulation in healthy
controls produces impairments in patterns of brain activity. L-dopa administration increased functional connectivity among the putamen, cerebellum, and brainstem, and
between the ventral striatum and ventrolateral prefrontal
cortex activity. It disrupted ventral striatum and dorsal caudate functional connectivity with the default mode network,
however [203]. Delaveau and colleagues [204, 205] showed
that L-dopa administration reduced bilateral amygdala activity, a region reciprocally connected to ventral striatum, in
healthy elderly volunteers performing a facial emotional
recognition task. Finally, Nagano-Saito and colleagues [181]
found changes in brain activity, which correlated with performance of the WCST, in healthy controls after consuming
a drink deficient in the dopamine precursors tyrosine and
phenylalanine compared to after they consumed a drink
balanced in amino acids. Following the balanced drink,
greater connectivity occurred between the frontal lobes and
striatum, correlating with faster set-shift response times, and
deactivation was noted in areas normally suppressed during
attention-demanding tasks, including the medial prefrontal
cortex, posterior cingulate cortex, and hippocampus. Following the dopamine precursor-depleted drink, fronto-striatal
connectivity was abolished and deactivations in medial
prefrontal cortex, posterior cingulate, and hippocampus
were no longer observed, associated with longer set shifting
response times.
5.4. Summary: Eﬀect of L-Dopa Administration on Neuroimaging Results. Overall, these results are consistent with
the notion that dopamine replacement normalizes activity in
the dorsal striatum and cortico-striatal networks that implicate dorsal striatum, both at rest and during performance of
cognitive tasks. These changes consist of increases in some
cortical regions and decreases in others, correlating with
improved performance on a variety of cognitive tasks such as
spatial working memory, selective attention, planning, and
set shifting.
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Dysfunctional patterns of brain activity precipitated
by dopamine replacement in PD are noted exclusively
for ventral striatum-mediated processes. Although only
Steeves and colleagues [200] observed direct dopamine
enhancement in the ventral striatum with dopamine agonist
administration, abnormal patterns of activity produced by
dopaminergic medication in PD patients solely implicated
brain regions that are reciprocally connected to the ventral
striatum. That is, reduced learning-related suppression in
ventromedial prefrontal cortex occurred during sequence
learning, increased activation of amygdala was noted on
tests of facial emotional recognition, and greater attenuation
of impulse control and response inhibition regions such
as the dorsal striatum, insula, cingulate, and orbitofrontal
cortex, were observed during more impulsive decisions in
PD patients treated with dopaminergic medications. The
studies reviewed here replicate the behavioural studies of
dopamine replacement in cognition and confirm that those
cognitive functions impaired by dopaminergic therapy in PD
are related to changes in the ventral striatum and cortical
networks that implicate the ventral striatum. The eﬀect of
dopamine supplementation in healthy controls on neural
activity in the ventral striatum-associated cortical networks
exactly mirrors the changes noted in PD, in line with the
ventral striatum dopamine over-supply account of cognitive
functions that worsen with treatment in PD.
We found rare direct but significant indirect evidence
that dopamine replacement improves some aspects of cognition by remediating dorsal striatum function and worsens
others by inducing pathological activity in ventral striatum.
Studies are needed that directly contrast dorsal versus ventral
striatum-mediated cognitive functions and associated neural
activity in the same PD patients, on and oﬀ medication.
Contrasting changes in brain activity noted for patients early
in the disease course relative to those observed with more
advanced disease will also enhance our understanding of
how the relation between dopamine replacement and these
divergent cognitive functions evolve in PD.

6. General Discussion
Cognitive dysfunction has long been recognized as a feature
of PD. Cognitive functions are increasingly attributed to the
basal ganglia [12–17, 19]. Dopamine replacement therapy
has contrasting eﬀects on diﬀerent cognitive functions. In
the current review, we present evidence that improvements
with dopamine replacement arise for cognitive processes
that are mediated by the dopamine-depleted dorsal striatum.
In contrast, cognitive operations that are impaired by
dopaminergic therapy are supported by the relatively spared
ventral striatum.
Selecting among alternative stimuli and responses, particularly when there is high conflict or when enacting a
decision requires disregarding previously relevant stimulus dimensions or responses, is improved by dopamine
replacement. Dopaminergic therapy also remediates longterm memory retrieval, planning, visuo-spatial processing,
as well as time estimation and motor-timing deficits. These
cognitive functions are ascribed to the dorsal striatum in
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studies of patients with dorsal striatum lesions and in
investigations of healthy controls using functional neuroimaging. Neuroimaging studies in PD confirm the notion
that dopamine replacement improves cognitive functions
mediated by dorsal striatum. Dopamine replacement normalizes activity in the dorsal striatum as well as in cortical
networks involving dorsal striatum both at rest and during
performance of cognitive tasks. These changes in neural
activity are associated with improvements in cognitive
performance.
In contrast, numerous studies reveal impaired probabilistic, associative, and sequence learning, decreased attentional
orienting, as well as poorer facial emotional recognition in
PD patients on relative to oﬀ dopamine replacement therapy.
Impulsivity is enhanced to a pathological degree in PD
patients on dopaminergic therapy. Studies of patients with
ventral striatum lesions and neuroimaging investigations
in healthy volunteers demonstrate that these behavioural
phenomena are mediated by the ventral striatum. Imaging
studies in PD on and oﬀ medication are therefore also consistent with the framework presented here for understanding
medication eﬀects on cognition in PD. Neuroimaging studies
in PD patients in the oﬀ state confirm that ventral striatum
and its cortical networks are unperturbed. Administration of
dopaminergic therapy produces abnormal patterns of brain
activity, with an increase in ventral striatal dopamine having
been noted and alterations in levels of activation of cortical
regions that are reciprocally connected to the ventral striatum being frequently observed. These neuroimaging changes
are associated with behavioural impairments in ventral
striatum-mediated cognitive processes. In line with claims
that the ventral striatum receives adequate dopamine innervation early in PD and that dopamine supplementation oversupplies this region resulting in abnormal ventral-striatum
mediated behaviour, the neuroimaging and behavioural consequences of dopamine supplementation in healthy controls
with respect to learning, facial emotion recognition, and
impulse control, exactly mirror those obtained with PD
patients.
Although ventral-striatum mediated cognitive processes
and their neural correlates are consistently adversely aﬀected
by dopamine supplementation in PD, medication-induced
eﬀects in learning, orienting, and facial emotional recognition suggest reduced, whereas increased impulsivity reflects
enhanced ventral striatum function. We speculate that these
contrasting eﬀects of dopamine replacement on ventral
striatum-mediated cognitive functions relate to their diﬀerential reliance on graded versus absolute ventral striatum
dopamine levels. Whereas dopamine replacement resulting
in excessive dopamine concentration in ventral striatum
conceivably disrupts processes that are informed by subtle
relative or phasic changes in dopamine level—perhaps
learning, orienting, and emotion discrimination, it might
pathologically enhance processes that are governed by
absolute or tonic dopamine signals. We submit that rapid
decision making, guided by heuristics rather than complete
consideration of all determinants and consequences of
behaviour (i.e., impulsivity) is enhanced to a detrimental
extent by dopamine replacement in PD.

Parkinson’s Disease
The cognitive profile in PD has many determinants.
The importance of each of these factors evolves over the
disease course. Some cognitive deficits owe to dopamine
deficiency in the dorsal striatum, which are at least partially
remediated by optimal dopaminergic therapy. In addition,
dopamine overdose of the ventral striatum reduces some
functions and heightens others to a pathological degree in
PD patients receiving dopamine replacement. As functional
neuroimaging studies demonstrate, dopamine deficiencies
and excesses in the dorsal and ventral striatum, as a function
of medication status, correlate with aberrant patterns of
neural activity in cortical networks that are directly or
even indirectly regulated by these respective brain regions.
Although not addressed in this paper, cognitive dysfunction
in PD also results from degeneration of cortex and other
neurotransmitter systems, especially with advancing disease.
Further, cortical regions receiving dopamine input from
VTA, such as prefrontal and limbic regions, are also likely
overdosed to varying extents by dopamine replacement in
PD, impacting cognitive functions that they mediate. Finally,
dopamine agonists and L-dopa have distinct mechanisms of
action with somewhat diﬀerent consequences on cognition
[206], an issue glossed over in this paper. In light of numerous variables interacting to produce patterns of cognitive
dysfunction and sparing in PD, given that these variables
are diﬀerentially aﬀected by dopaminergic therapy in general
and by type of therapy specifically, and finally, because
these interactions evolve over disease course, the framework
adopted in this paper is clearly an over-simplification.
That notwithstanding, it accommodates and explains an
impressive array of cognitive and neuroimaging findings,
providing a basic tenet for predicting and understanding the
eﬀect of dopamine replacement therapy on cognition in PD.
6.1. Controversies and Areas Warranting Further Investigation.
Our review brings to light a number of inconsistencies as well
as areas that warrant further consideration. Although dorsal
striatum is implicated in selective attention and decision
making, the specific aspect of these situations that depends
upon the dorsal striatum remains somewhat unclear. Occasionally these executive functions are unimpaired in patients
with dorsal striatum lesion or PD, and are not associated
with preferential activation of the dorsal striatum using
neuroimaging. We submit that decisions requiring integration of multiple dimensions, particularly those that require
resolving conflicting influences on responding, depend to the
greatest extent on the dorsal striatum. We predict that these
instances will be most improved by dopamine replacement.
Further investigation, however, is required.
With respect to the ventral striatum, whether this region
mediates encoding for implicit or explicit uses of memory
diﬀerentially has not yet been directly investigated although
our survey of the literature does not suggest such specificity.
Further, although the eﬀects of dopamine replacement
are consistently adverse with respect to ventral-striatum
mediated behavior, some functions are reduced whereas
others are pathologically enhanced. We argue that this relates
to whether a function derives from graded, phasic dopamine
responses, which bolus dopamine treatment will interrupt,
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versus absolute dopaminergic tone that will be heightened
by dopamine replacement. Direct empirical investigations of
this hypothesis are needed.
Finally, studies aimed specifically at contrasting dorsal
versus ventral striatum-mediated cognitive functions in PD
patients on and oﬀ medication relative to controls using
neuroimaging are lacking. These studies will provide a
greater understanding of the changes within the dorsal and
ventral striato-cortical networks that occur in PD and how
these are modulated by dopamine therapy. Investigations of
how these interactions evolve over the disease course will
also improve our understanding of the eﬀect of dopamine
replacement on cognition in PD.

7. Conclusion
This review highlights the fact that currently, titration of
therapy in PD is geared to optimizing dorsal striatummediated motor symptoms, at the expense of ventral
striatum-mediated operations. This consequence is only
beginning to be recognized and the impact fully appreciated.
Enhanced awareness of the diﬀerential eﬀects of dopamine
replacement on disparate cognitive functions will translate
to medication strategies that take into account both those
symptoms that dopamine replacement might improve versus
hinder. Ultimately, this knowledge will lead clinicians to survey a broader range of symptoms and signs in determining
optimal therapy based on individual patient priorities.
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and R. G. Schlösser, “Assessing the neural basis of uncertainty
in perceptual category learning through varying levels of
distortion,” Journal of Cognitive Neuroscience. In press.
[73] N. D. Daw and K. Doya, “The computational neurobiology of
learning and reward,” Current Opinion in Neurobiology, vol.
16, no. 2, pp. 199–204, 2006.
[74] M. R. Delgado, M. M. Miller, S. Inati, and E. A. Phelps,
“An fMRI study of reward-related probability learning,”
NeuroImage, vol. 24, no. 3, pp. 862–873, 2005.
[75] H. Ohira, N. Ichikawa, M. Nomura et al., “Brain and
autonomic association accompanying stochastic decisionmaking,” NeuroImage, vol. 49, no. 1, pp. 1024–1037, 2010.
[76] J. T. Coull, R.-K. Cheng, and W. H. Meck, “Neuroanatomical
and neurochemical substrates of timing,” Neuropsychopharmacology, vol. 36, no. 1, pp. 3–25, 2011.
[77] JT. T. Coull and AC. C. Nobre, “Dissociating explicit timing
from temporal expectation with fMRI,” Current Opinion in
Neurobiology, vol. 18, no. 2, pp. 137–144, 2008.
[78] A. M. Ferrandez, L. Hugueville, S. Lehéricy, J. B. Poline, C.
Marsault, and V. Pouthas, “Basal ganglia and supplementary
motor area subtend duration perception: an fMRI study,”
NeuroImage, vol. 19, no. 4, pp. 1532–1544, 2003.
[79] D. L. Harrington, L. A. Boyd, A. R. Mayer et al., “Neural
representation of interval encoding and decision making,”
Cognitive Brain Research, vol. 21, no. 2, pp. 193–205, 2004.
[80] D. L. Harrington, J. L. Zimbelman, S. C. Hinton, and
S. M. Rao, “Neural modulation of temporal encoding,
maintenance, and decision processes,” Cerebral Cortex, vol.
20, no. 6, pp. 1274–1285, 2010.
[81] M. Jahanshahi, C. R. G. Jones, G. Dirnberger, and C. D.
Frith, “The substantia nigra pars compacta and temporal
processing,” Journal of Neuroscience, vol. 26, no. 47, pp.
12266–12273, 2006.
[82] I. Nenadic, C. Gaser, H. P. Volz, T. Rammsayer, F. Häger,
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